GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- B5921 Cyclosporin HSummary: Selective and competitive formyl peptide receptor antagonist
- B5925 ELN441958Summary: Potent and selective bradykinin B1 receptor antagonist
- B5944 Carteolol HClSummary: Non-selective beta-adrenoceptor antagonist
- B4575 AL 8810Target: prostaglandin FP receptorSummary: Antagonist of prostaglandin F2α (FP) receptor.
- B5994 Cyclobenzaprine HClSummary: 5-HT2 receptor antagonist
- B6038 Ozanimod (RPC1063)Summary: agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5
- B1283 Prasugrel hydrochlorideSummary: P2 Receptor inhibitor
- B1535 OC000459Summary: Antagonist of D prostanoid receptor 2 ,potent and selective
- B2254 SB269970 HClSummary: 5-HT7 receptor antagonist,potent and selective
- B1629 VU 0357121Summary: Novel positive allosteric modulator (PAM) of mGlu5